Screener
Corvus Pharmaceuticals CRVS Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net loss | $(13,692) | $15,193 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 29 | 22 |
| Accretion related to marketable securities | (17) | (291) |
| Stock-based compensation | 2,650 | 1,251 |
| Change in fair value of warrant liability | — | (25,129) |
| Loss from equity method investment | 599 | 539 |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Corvus Pharmaceuticals (CRVS) reported accretion (amortization) of discounts and premiums, investments of $17K in Q1 2026.
- How has Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 94.2% year-over-year, from $291K to $17K.
- What is the long-term trend for Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2022 to 2025), Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 99.3% compound annual growth rate (CAGR), from $170K to $1.35M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of discounts or premiums on debt securities held as investments. It reflects the gradual recognition of the difference between the purchase price and the face value of investment securities over their holding period. This adjustment is essential for reconciling net income to cash flow from operations by removing non-cash yield components.
Ask your AI about Corvus Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude